GlassScriptPhysician profile
Lashawn Chapman
NPI 1588018808
$3,497.44
in general payments reported to CMS, 2019-2025
36 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $585 · 2022: $535 · 2023: $1,125 · 2024: $1,065 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,376.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $647.80 | 2021-2025 | Evenity, Prolia |
| Ucb, INC. | $408.98 | 2023-2024 | Briviact, Fintepla, Rystiggo |
| Takeda Pharmaceuticals U.S.A., INC. | $256.83 | 2022-2024 | Hyqvia |
| Astrazeneca Pharmaceuticals LP | $249.68 | 2021-2022 | |
| Tg Therapeutics, INC. | $209.86 | 2023-2025 | |
| Lilly USA, LLC | $174.22 | 2023-2024 | Emgality, Amyvid, Reyvow |
| Lundbeck LLC | $156.10 | 2021-2024 | Vyepti, Rexulti |
| Merz Pharmaceuticals, LLC | $150.72 | 2023-2024 | Xeomin |
| Janssen Scientific Affairs, LLC | $124.51 | 2021 | |
| Amag Pharmaceuticals, INC. | $111.71 | 2021 | |
| Sk Life Science, INC. | $84.79 | 2023-2024 | |
| Octapharma USA, INC. | $71.82 | 2024 | Panzyga, Octagam Immune Globulin (Human) |
| Eisai INC. | $69.24 | 2023-2024 | |
| Pharmacosmos Therapeutics INC. | $62.48 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $57.51 | 2024 | Dysport |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $57.42 | 2024 | Daybue |
| Grifols USA, LLC | $54.32 | 2023-2025 | Gamunex-C, Prolastin-C Liquid |
| Scilex Pharmaceuticals INC. | $51.53 | 2024 | |
| Alnylam Pharmaceuticals INC. | $46.80 | 2023 | Onpattro |
| Sumitomo Pharma America, INC. | $45.44 | 2023 | Aptiom |
| Neurocrine Biosciences, INC. | $44.38 | 2023 | Ongentys, Ingrezza |
| Kedrion Biopharma, INC. | $40.18 | 2024 | Koate, Kedrab, Gammaked |
| Alexion Pharmaceuticals, INC. | $38.08 | 2024 | Soliris, Ultomiris |
| Biogen, INC. | $36.33 | 2023-2024 | Skyclarys, Skyclarys |
| Janssen Biotech, INC. | $32.00 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $28.35 | 2024 | Austedo Xr |
| Neurelis, INC. | $27.77 | 2024 | Valtoco |
| Argenx US, INC. | $22.51 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Csl Behring | $21.58 | 2023 | Hizentra |
| Corium, LLC | $20.10 | 2023 | Adlarity |
| Emd Serono, INC. | $18.44 | 2023 | Mavenclad |
| Abbvie INC. | $17.53 | 2023 | |
| Amneal Pharmaceuticals LLC | $16.92 | 2024 | Rytary |
| Grt US Holding, INC. | $16.37 | 2021 | |
| Jazz Pharmaceuticals INC. | $12.82 | 2023 | |
| Glaxosmithkline, LLC. | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lashawn Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.